New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Article

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Related Videos
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
A panel of 3 experts on dry eye
1 KOL is featured in this series.
1 KOL is featured in this series.
Shawn Kwatra, MD, an expert on atopic dermatitis
Shawn Kwatra, MD, an expert on atopic dermatitis
Ruth Ann Vleugels, MD, MPH, MBA, an expert on atopic dermatitis
Ruth Ann Vleugels, MD, MPH, MBA, an expert on atopic dermatitis
Brendon Neuen, MBBS, PhD | Credit: X.com
Sorana Segal-Maurer, MD, an expert on HIV
© 2024 MJH Life Sciences

All rights reserved.